GB202203627D0 - Agents for treating complement-related disorders - Google Patents

Agents for treating complement-related disorders

Info

Publication number
GB202203627D0
GB202203627D0 GBGB2203627.1A GB202203627A GB202203627D0 GB 202203627 D0 GB202203627 D0 GB 202203627D0 GB 202203627 A GB202203627 A GB 202203627A GB 202203627 D0 GB202203627 D0 GB 202203627D0
Authority
GB
United Kingdom
Prior art keywords
agents
related disorders
treating complement
complement
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2203627.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Complement Therapeutics Ltd
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Priority to GBGB2203627.1A priority Critical patent/GB202203627D0/en
Publication of GB202203627D0 publication Critical patent/GB202203627D0/en
Priority to PCT/EP2023/056794 priority patent/WO2023175099A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
GBGB2203627.1A 2022-03-16 2022-03-16 Agents for treating complement-related disorders Ceased GB202203627D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2203627.1A GB202203627D0 (en) 2022-03-16 2022-03-16 Agents for treating complement-related disorders
PCT/EP2023/056794 WO2023175099A1 (en) 2022-03-16 2023-03-16 Agents for treating complement-related disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2203627.1A GB202203627D0 (en) 2022-03-16 2022-03-16 Agents for treating complement-related disorders

Publications (1)

Publication Number Publication Date
GB202203627D0 true GB202203627D0 (en) 2022-04-27

Family

ID=81255000

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2203627.1A Ceased GB202203627D0 (en) 2022-03-16 2022-03-16 Agents for treating complement-related disorders

Country Status (2)

Country Link
GB (1) GB202203627D0 (en)
WO (1) WO2023175099A1 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200401292T3 (en) 2000-12-01 2004-07-21 Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften the rnaágirişimineáyoláaçanáküçükárnaámolekül
CA2666843C (en) 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
EP2851432B1 (en) 2007-11-01 2019-01-09 University of Iowa Research Foundation RCA locus analysis to assess susceptibility to AMD
BR112014013205A2 (en) 2011-12-01 2020-10-27 Protevobio, Inc. fusion protein, its use and production method, pharmaceutical composition, nucleic acid, and kit
JP6026639B2 (en) 2012-04-02 2016-11-16 ソンギュン バイオテック カンパニー リミテッドＳｕｎｇ Ｋｙｕｎ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． Composition for prevention and treatment of bone metabolic disease containing extract of genus Fujibacama and method for producing the same
EP3884949A1 (en) 2012-06-08 2021-09-29 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
PL3474883T3 (en) 2016-06-28 2022-09-19 Universität Ulm Complement inhibitors and uses thereof
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3791180A1 (en) 2018-05-10 2021-03-17 The University Of Manchester Methods for assessing macular degeneration
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
GB202006789D0 (en) * 2020-05-07 2020-06-24 Univ Manchester Detection of complement proteins
EP4214515A1 (en) 2020-09-16 2023-07-26 Complement Therapeutics Limited Complementome assay

Also Published As

Publication number Publication date
WO2023175099A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
IL285649A (en) Azepino-indoles and other heterocycles for treating brain disorders
IL289173A (en) Compositions and methods for treating cns disorders
IL294594A (en) Methods for treating pemphigus disorders
IL310975A (en) Lou064 for treating multiple sclerosis
IL289172A (en) Compositions and methods for treating cns disorders
IL290770A (en) Compounds and methods for treating oxalate-related diseases
GB202203627D0 (en) Agents for treating complement-related disorders
IL288234A (en) Compounds for the treatment of neuromuscular disorders
IL291476A (en) Pharmacological composition for treating proctological diseases (variants)
IL292186A (en) Compositions and methods for treating blood disorders
IL307607A (en) Tetracyclic compounds for treating brain disorders
EP4054567A4 (en) Treating liver disorders
GB202002038D0 (en) Compounds for treating bone disorders
GB202116350D0 (en) Agents for treating senescence-associated diseases or disorders
GB202007652D0 (en) Compounds for treating covid-19
IL308424A (en) Use of pelabresib for treating anemias
GB202314527D0 (en) New treatment for pain
GB201912449D0 (en) Compounds for treatment of neovascular diseases
GB202308670D0 (en) New formulations for treating opioid use disorder
GB202304716D0 (en) New treatment
GB202210430D0 (en) New treatment
EP4084795A4 (en) Compounds and compositions for treating cns disorders
EP4084797A4 (en) Compounds and compositions for treating cns disorders
GB202206219D0 (en) New treatment
GB201902790D0 (en) Methods for assessing and treating complement-related disorders

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: COMPLEMENT THERAPEUTICS LIMITED

Free format text: FORMER OWNER: THE UNIVERSITY OF MANCHESTER,

AT Applications terminated before publication under section 16(1)